# Clinical Trials Data EGFR - Document 57

# Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities

## Clinical Trial: https://clinicaltrials.gov/study/NCT01758575

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients that will start palliative treatment with TKIs, mTOR inhibitors, ipilimumab, vemurafenib or EGFR inhibitors and therefore fulfill according to their attending physician all the usual criteria for receiving standard targeted therapy as monotherapy.\n2. PT-INR/PTT \\< 1.5 x ULN.\n3. Platelet count \\>/= 100 x 109/l\n\nExclusion Criteria:\n\n1. Concomitant use of anticoagulants\n2. Previous colonic surgery in the last 3 months\n3. History of inflammatory bowel disease, or other active gastrointestinal infection",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with advanced or metastatic solid malignancy, amenable to standard treatment with targeted agents will be included from the VUmc Medical Oncology outpatient clinic.",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient with an EGFR gene mutation would be eligible. The inclusion criteria specify that patients starting palliative treatment with EGFR inhibitors are eligible, which implies targeting EGFR gene mutations is a part of the trial's focus. Additionally, the criteria mention that patients must fulfill the conditions for receiving standard targeted therapy, which would likely apply to someone with an EGFR mutation. Therefore, as long as the patient does not meet any of the exclusion criteria, they would be eligible for the trial.